Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

Survival estimate remained at 48% between years two and three, extending evidence of durable benefit Results observed in heavily pretreated, difficult-to-treat population that received a median of four prior lines of therapy; nearly three-quarters of patients had platinum-resistant or refractory cancer LEXINGTON, Mass. — Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today…

We haven't written up this one. Financial Post has the full story — the link below goes straight to it.

Read the original at financialpost.com →

More in Health & Medicine

Treat healthcare as an investment, not a budget cost – Mahama

President John Dramani Mahama has called on African governments and investors to fundamentally change the way they approach healthcare financing, arguing that health must be treated as an investable economic sector rather than a social expenditure to be funded only when resources are available.

More from Saturday 3 October →